These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15307103)

  • 1. Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma.
    Nola M; Pavletic SZ; Weisenburger DD; Smith LM; Bast MA; Vose JM; Armitage JO
    Am J Hematol; 2004 Sep; 77(1):31-5. PubMed ID: 15307103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical tumor cell distribution pattern is a prognostically relevant parameter in patients with B-cell chronic lymphocytic leukemia.
    Jaksic O; Vrhovac R; Kusec R; Kardum MM; Pandzic-Jaksic V; Kardum-Skelin I; Planinc-Peraica A; Morabito F; Brugiatelli M; Jaksic B
    Haematologica; 2001 Aug; 86(8):827-36. PubMed ID: 11522539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
    Tsimberidou AM; O'Brien S; Kantarjian HM; Koller C; Hagemeister FB; Fayad L; Lerner S; Bueso-Ramos CE; Keating MJ
    Cancer; 2006 Sep; 107(6):1294-302. PubMed ID: 16902984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
    Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
    Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
    Wolowiec D; Wojtowicz M; Ciszak L; Kosmaczewska A; Frydecka I; Potoczek S; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
    Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic parameters in low-grade non-Hodgkin's lymphomas.
    Zemunik T; Vucković J; Forenpoher G; Knezević N; Stula N; Dubravcić M; Ribicić I; Rozga A
    Neoplasma; 1997; 44(1):13-7. PubMed ID: 9201275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
    Sonnen R; Schmidt WP; Müller-Hermelink HK; Schmitz N
    Br J Haematol; 2005 May; 129(3):366-72. PubMed ID: 15842660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for pleural lymphoma patients.
    Aozasa K; Ohsawa M; Iuchi K; Mori T; Komatsu H; Tajima K; Minato K; Tajima K; Shimoyama M
    Jpn J Clin Oncol; 1991 Dec; 21(6):417-21. PubMed ID: 1805046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomorphologic spectrum of small lymphocytic lymphoma in patients with an accelerated clinical course.
    Shin HJ; Caraway NP; Katz RL
    Cancer; 2003 Oct; 99(5):293-300. PubMed ID: 14579296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost determinants in aggressive non-Hodgkin's lymphoma.
    van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
    Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.